Heartland Bank & Trust Co Cuts Stock Holdings in Danaher Co. (NYSE:DHR)

Heartland Bank & Trust Co lowered its stake in shares of Danaher Co. (NYSE:DHR) by 5.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,077 shares of the conglomerate’s stock after selling 162 shares during the quarter. Heartland Bank & Trust Co’s holdings in Danaher were worth $706,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. FMR LLC raised its holdings in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares in the last quarter. International Assets Investment Management LLC increased its stake in Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after buying an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. lifted its position in shares of Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after buying an additional 397,671 shares in the last quarter. Finally, Union Bancaire Privee UBP SA purchased a new position in shares of Danaher in the 4th quarter worth approximately $74,551,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on DHR. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Scotiabank initiated coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a research report on Thursday, October 31st. Robert W. Baird lowered their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, TD Cowen increased their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $285.55.

Danaher Price Performance

DHR stock opened at $245.95 on Monday. The firm has a 50 day moving average of $235.33 and a 200-day moving average of $253.62. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $177.65 billion, a P/E ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.